Frank Schestag, PhD, Joins Proteintech as Commercial Director in Europe
Proteintech, the benchmark in antibodies and proteins, welcomes Frank Schestag, PhD, as Commercial Director. He will be providing leadership to the sales and marketing teams and growing the markets in Germany, Austria, and Switzerland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190710005684/en/
Dr. Frank Schestag, Proteintech Commercial Director (Photo: Business Wire)
Dr. Schestag comes to Proteintech with 18 years of experience in sales and management of scientific reagents and equipment. At Fisher Scientific as Director of Sales and then promoted to Senior Sales Director of the Life Science Solution Group (Life Technologies), he led teams over 50 sales specialists in central Europe and responsible for over $200M in revenue. Throughout his career, Dr. Schestag has exceled in building teams, whether it be technical support, sales, logistics, or accounting. Besides high performance, his sites have consistently scored the highest in employee satisfaction and engagement.
“Europe has always been at the forefront of science. Frank’s experience in leadership will enable us to better serve Europe’s scientific community as well as the pharmaceutical and biomedical communities,” says Proteintech CEO Jason Li.
“I am very excited to become a member of the Proteintech Group. For me, it is a perfect fit to support Proteintech with the experience I have gained in the last 20 years in science, sales, operations, and the European market,” says new Proteintech Commercial Director, Dr. Frank Schestag, “I believe it will bring us more successes than we’re already seeing today.”
Dr. Schestag received his PhD in Biochemistry at the Christian-Albrechts-University in Kiel. Afterward, he began his career at Fermentas, a manufacturer of molecular biology products. He was responsible for developing the business in technical support, customer service, and commercial organization. As the Sales Director for Europe, he built up and led a direct sales team operating in 15 different European countries. In large part due to Dr. Schestag’s stewardship, Fermentas accelerated in growth and was acquired by Thermo Fisher, where he transitioned to General Manager and Site Leader. Through these experiences, Dr. Schestag has gained an intimate knowledge of the German market and how to drive growth there.
About Proteintech Group
Proteintech is an antibody manufacturer selling directly to scientists and only selling its own products to maintain the highest level of quality control leading to superior reproducibility and lot consistency. With over 2/3 of the human genome completed, we have a catalog of over 12,000 antibodies against 12,000 targets covering nearly all research areas. With its acquisition of Humanzyme, Proteintech now offers the Humankine® product line of animal-free human-cell expressed proteins. To view tens of thousands of publications and in-house validation images in WB, IHC, IF, FC, IP, CHIP, and KD/KO siRNA experiments using our antibodies and to learn more about Proteintech and their mission to deliver products directly from their bench to the researcher’s bench, please visit www.ptglab.com
Proteintech Group, Inc.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ResMed Inc. Completes $500M Private Placement Debt Offering15.7.2019 20:05:00 CEST | Press release
ResMed Inc. (NYSE: RMD, ASX: RMD) announced today the successful pricing and closing of a private placement offering of $250,000,000 principal amount 3.24% senior notes due July 10, 2026, and $250,000,000 principal amount 3.45% senior notes due July 10, 2029. Net proceeds from the offering will be approximately $498 million, after deducting estimated fees and expenses related to the offering. The net proceeds will be used to pay down current borrowings on ResMed’s senior unsecured revolving credit facility. The notes are senior unsecured obligations of ResMed, and jointly and severally guaranteed by each Subsidiary Guarantor. “We are pleased to complete this U.S. private placement offering on attractive terms,” said Brett Sandercock, ResMed’s chief financial officer. “The transaction significantly lengthens our average debt maturity profile and provides improved visibility on our long-term funding costs.” This private placement offering is exempt from the registration requirements of t
SpeeDx Receives Clearance from Health Canada for ResistancePlus® MG Test15.7.2019 15:00:00 CEST | Press release
SpeeDx Pty. Ltd. today announced Resistance Plus® MG has been cleared by Health Canada and is now available for sale across all Canadian provinces (not currently available in the U.S.). The molecular diagnostic test detects the sexually transmitted infection (STI) Mycoplasma genitalium, also known as Mgen, along with genetic markers linked to antibiotic resistance. This is the first commercially available test in Canada combining identification and therapeutic guidance information to support Resistance Guided Therapy for management of Mgen. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190715005544/en/ (Photo: Business Wire) Current Canadian management guidelines for Mgen direct laboratories to forward positive samples to the National Microbiology Laboratory for resistance testing.1 Now Canadian laboratories can utilize Resistance Plus MG and bring this service inhouse to generate more timely results for doctors and their p
Mouser Electronics Now Stocking Broad Portfolio of Xilinx Products15.7.2019 14:55:00 CEST | Press release
Mouser Electronics, Inc. today announces a new global distribution agreement with Xilinx, Inc., the leader in adaptive and intelligent computing, to stock one of the industry’s broadest portfolios of Xilinx products, including digital downloads of development software and IP. Xilinx is the inventor of the FPGA, hardware programmable system-on-chips (SoCs) and the adaptive compute acceleration platform (ACAP), designed to deliver the most dynamic processor technology in the industry and enable the adaptable, intelligent and connected world of the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190715005546/en/ Mouser Electronics proudly announces a new global distribution agreement with Xilinx, Inc., the leader in adaptive and intelligent computing. Mouser will stock one of the industry’s broadest portfolios of Xilinx products. (Graphic: Business Wire) To learn more, visit www.mouser.com/xilinx. “Xilinx is an industry
Rimini Street Becomes Support Service Provider for Hyundai-Kia Motors’ Global Database Portfolio15.7.2019 13:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that it has been selected as the software support services provider to global auto manufacturer Hyundai-Kia Motors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190715005161/en/ Rimini Street announced that it has been selected as the software support services provider to global auto manufacturer Hyundai-Kia Motors. (Photo: Business Wire) By providing efficient, timely, and cost-effective database maintenance and support, Rimini Street plans to actively support Hyundai-Kia Motors in their endeavor to implement a business-driven IT roadmap. Cost Optimization and Desire for Quality Support To support response to paradigm shifts in the automobile industry and active technology innovation, Hyundai-Kia Motors se
Värde Partners Appoints Co-CEO15.7.2019 12:12:00 CEST | Press release
Värde Partners, a leading global alternative investment firm, today announced that Ilfryn Carstairs will join George Hicks, Co-Founder and Chief Executive Officer, as Co-CEO, effective January 1, 2020. George co-founded Värde Partners 25 years ago and intends to transition to an Executive Chair role in 2022. Ilfryn will retain his role as Global CIO. “Transition is a process and involves the entirety of the firm. The roles Ilfryn and I play are just part of that process whereby a new generation of leaders succeed the founders,” said George. “Ilfryn joined us 12 years into this journey and has grown as both an investor and a leader. His skills in both pursuits will enable Värde to continue delivering for our investors and will help to ensure that we maintain our strong culture long into the future.” Ilfryn is a Partner and Co-Chief Investment Officer overseeing the global investment strategy for Värde. He co-chairs the firm’s Investment Committee. Based in Singapore since 2017, he joine
Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform15.7.2019 12:00:00 CEST | Press release
Boehringer Ingelheim today announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL’s lead vaccine ATP128 is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this month. Boehringer Ingelheim plans to develop new therapies by combining assets from its cancer immunology portfolio with AMAL’s proprietary KISIMA immunization platform. “Acquiring AMAL is part of Boehringer Ingelheim’s long-term strategy to enhance our existing position as an innovator of novel cancer therapies, including immuno-oncology treatments, which leverage cutting-edge scientific discoveries and their applications,” said Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the company’s Innovation Unit. “We want to pioneer new paradigms